Mujammami, M.; Aleidi, S.M.; Buzatto, A.Z.; Alshahrani, A.; AlMalki, R.H.; Benabdelkamel, H.; Al Dubayee, M.; Li, L.; Aljada, A.; Abdel Rahman, A.M.
Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential. Pharmaceuticals 2023, 16, 1717.
https://doi.org/10.3390/ph16121717
AMA Style
Mujammami M, Aleidi SM, Buzatto AZ, Alshahrani A, AlMalki RH, Benabdelkamel H, Al Dubayee M, Li L, Aljada A, Abdel Rahman AM.
Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential. Pharmaceuticals. 2023; 16(12):1717.
https://doi.org/10.3390/ph16121717
Chicago/Turabian Style
Mujammami, Muhammad, Shereen M. Aleidi, Adriana Zardini Buzatto, Awad Alshahrani, Reem H. AlMalki, Hicham Benabdelkamel, Mohammed Al Dubayee, Liang Li, Ahmad Aljada, and Anas M. Abdel Rahman.
2023. "Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential" Pharmaceuticals 16, no. 12: 1717.
https://doi.org/10.3390/ph16121717
APA Style
Mujammami, M., Aleidi, S. M., Buzatto, A. Z., Alshahrani, A., AlMalki, R. H., Benabdelkamel, H., Al Dubayee, M., Li, L., Aljada, A., & Abdel Rahman, A. M.
(2023). Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential. Pharmaceuticals, 16(12), 1717.
https://doi.org/10.3390/ph16121717
